Diabetes in the UK 2026: An Accelerating Crisis
Diabetes has become the United Kingdom’s fastest-growing long-term health condition, and the scale of the problem in 2026 is staggering by any measure. Over 5.6 million people in the UK are currently living with diabetes — an all-time high — with a further 13.6 million people at high risk of developing type 2 diabetes. Together, that means more than 1 in 3 Britons are directly affected by diabetes or its precursor condition, placing extraordinary and growing pressure on the NHS, on workplace productivity, and on the quality of life of millions of families. The number of people with a confirmed diabetes diagnosis has more than doubled from around 1.9 million in England in 2000 to over 4.4 million in England alone today — a doubling in just over two decades driven primarily by rising obesity, increasingly sedentary lifestyles, and an ageing population.
The financial consequences are equally enormous. Diabetes costs the NHS approximately £10.7 billion per year — around 10% of the entire NHS budget in England — according to a major 2024 analysis commissioned by Diabetes UK and carried out by the York Health Economics Consortium at the University of York. Including indirect costs such as lost workplace productivity and premature death, the total cost of diabetes to the UK reached almost £14 billion in 2021/22, and is forecast to reach nearly £18 billion by 2035. Critically, approximately £6.2 billion of NHS diabetes spending goes on complications — the amputations, heart failures, strokes, and kidney failures that arise when diabetes is poorly managed — the majority of which are largely preventable with better early care. In 2026, Britain is spending more on diabetes than ever before, and the overwhelming consensus from researchers, clinicians, and public health officials is that it is still nowhere near enough.
Key Diabetes Facts in the UK 2026
UK DIABETES — FAST FACTS SNAPSHOT (2026)
=========================================
People with diabetes (UK total) ████████████████████████ 5.6 million+
People with diabetes (England only) ████████████████████████ 4.4 million+
Type 2 share of all cases ████████████████████████ ~90%
Type 1 share of all cases ██ ~8%
At high risk of type 2 (pre-diabetes) ████████████████████████ 13.6 million
Undiagnosed type 2 (estimate) ███ ~1.3 million
Annual NHS cost — diabetes ████████████████████████ £10.7 billion (~10% budget)
Total UK cost incl. indirect (2021/22)████████████████████████ ~£14 billion
Forecast NHS cost by 2035 ████████████████████████ ~£18 billion
► Diabetes diagnoses in England more than doubled: 1.9M (2000) → 4.4M+ (2026)
| Key Fact | Data Point |
|---|---|
| Total people with diabetes in the UK (2026) | Over 5.6 million — an all-time high (BritClock / Diabetes UK, 2026) |
| People with diabetes in England and Wales (NHS Digital, 2023/24) | Over 4.4 million registered — including 3.5 million+ type 2 and ~277,000 type 1 in England |
| People with diabetes in Scotland (2023) | 353,088 — up 13% in five years (NHS Scotland) |
| People with diabetes in Northern Ireland (2024/25) | 117,711 — more than double the 2004/05 figure (NI Department for Health) |
| Type 2 diabetes as share of all UK cases | ~90% — the dominant and rapidly growing type |
| Type 1 diabetes as share of all UK cases | ~8% — autoimmune condition; no known prevention |
| People at high risk of type 2 diabetes (UK, 2026) | 13.6 million — Diabetes UK / NHS |
| Estimated undiagnosed type 2 diabetes (UK) | ~1.3 million people — Diabetes UK estimate |
| Adults living with pre-diabetes (ONS) | 5.1 million adults — including 1 million with undiagnosed type 2 in England |
| Annual NHS diabetes spending (England) | £10.7 billion — ~10% of entire NHS England budget (York Health Economics Consortium, 2024) |
| NHS spend on diabetes complications specifically | £6.2 billion — approximately 60% of NHS diabetes spending on largely preventable complications |
| NHS spend on routine diabetes care | £4.4 billion — covering diagnosis, GP appointments, screening, medication, technology |
| Total UK cost of diabetes incl. indirect costs (2021/22) | ~£14 billion — University of York / Diabetes UK (published Diabetic Medicine, 2024) |
| Indirect cost of diabetes (productivity losses, premature death) | £3.3 billion annually |
| Forecast NHS diabetes cost by 2035 | Nearly £18 billion — Diabetes UK / York projection |
| Doubling of diagnoses in England | From 1.9 million (2000) to over 4.4 million today — more than doubled in 25 years |
Source: BritClock — UK Diabetes Statistics 2026 (May 2026, citing Diabetes UK / NHS Digital); Diabetes UK — How Many People in the UK Have Diabetes? (2026); York Health Economics Consortium / University of York — Cost of Illness Analysis (Diabetic Medicine, June 2024); NHS Digital — National Diabetes Audit 2023/24 (December 2024); NHS Scotland Diabetes Statistics 2023; NI Department for Health Diabetes Register 2024/25; Chemist-4-U — UK Diabetes Statistics (updated February 2026); ONS / Parliamentary Committee evidence
The scale of 5.6 million people with diabetes alongside 13.6 million more at high risk means that the diabetic and pre-diabetic population of the UK now encompasses a group larger than the entire population of Scotland and Northern Ireland combined. This is not a condition affecting a small minority — it is reshaping the burden of disease at a national level. The finding that roughly £6.2 billion of the NHS’s £10.7 billion annual diabetes spend goes on managing complications — the avoidable consequences of late diagnosis, inadequate monitoring, or poor blood sugar control — is one of the most important and most damning statistics in UK public health. It means the NHS is spending the majority of its diabetes budget on the consequences of diabetes rather than on preventing them. As the York Health Economics Consortium stated plainly, “the majority of those costs are still spent on potentially preventable complications.”
The forecast of nearly £18 billion in annual NHS diabetes costs by 2035 — up from £10.7 billion now — is not a worst-case scenario. It is a trajectory based on current trends in diagnosis, obesity, and population ageing, with no dramatic acceleration assumed. If nothing changes, the NHS will be spending roughly one pound in every seven of its entire budget on a single condition within the decade. That fiscal reality is driving every major diabetes policy development in 2026, from the expansion of the NHS Healthier You Prevention Programme to the government’s obesity strategy and the post-COVID focus on restoring diabetes care processes that were disrupted during the pandemic.
Type 1 and Type 2 Diabetes in the UK 2026
UK DIABETES BY TYPE — BREAKDOWN (2023/24 NHS DIGITAL DATA)
===========================================================
Type 2 (England & Wales, 2023/24) ████████████████████████████ 3.5 million+
Type 1 (England & Wales, 2023/24) ██ ~277,000
Type 2 — % of all cases ████████████████████████████ ~90%
Type 1 — % of all cases ██ ~8%
Other/gestational/unspecified █ ~2%
Children & YP with type 2 (E&W) ░ 1,359 (NPDA 2025)
UK: 2nd highest T1D in children ████████████████████████████ Europe (after Germany)
Under-40 T2D rate — change ████████████████████████████ More than doubled (past decade)
► Type 2 diagnoses in under-40s now rising faster than in over-40s for first time
| Diabetes Type Metric | Data |
|---|---|
| Type 2 diabetes — registered in England and Wales (2023/24) | Over 3.5 million — NHS Digital National Diabetes Audit |
| Type 1 diabetes — registered in England and Wales (2023/24) | ~277,000 — NHS Digital; 44.7% aged 40 and under |
| Type 2 diabetes — share of all UK diabetes cases | ~90% |
| Type 1 diabetes — autoimmune condition; no known prevention | ~8% of UK cases; requires daily insulin management |
| Gestational diabetes (GDM) — England per year | ~30,000 out of 700,000 births — NHS England; affects ~1 in 20 pregnancies in UK |
| GDM → type 2 risk | Up to 50% of women diagnosed with GDM develop type 2 diabetes within 5 years |
| Children and young people with type 2 (England and Wales, NPDA 2025) | 1,359 — National Paediatric Diabetes Audit 2025; 97.4% in England |
| Under-40s with type 2 diabetes — trend | More than doubled in the past decade — a particularly alarming trajectory |
| Type 2 in under-40s vs. over-40s | For the first time, diagnoses in under-40s are rising faster than in over-40s |
| UK children with type 1 diabetes (2021, IDF/Statista) | Over 31,600 — 2nd highest number in Europe after Germany |
| Average glycated haemoglobin (HbA1c) — most deprived CYP with type 1 | 66.6 mmol/mol (2023/24) — vs. 60.0 in least deprived areas — NPDA 2025 |
| Type 2 remission — NHS DiRECT trial | Around 50% of participants achieved remission through an 800-calorie liquid diet; requires ~10–15 kg weight loss |
Source: NHS Digital — National Diabetes Audit 2023/24 (December 2024); National Paediatric Diabetes Audit 2025 (RCPCH / HQIP); Statista — Diabetes in England and Wales by Type 2023/24; BritClock UK Diabetes 2026; NHS England — Gestational Diabetes Statistics; Chemist-4-U UK Diabetes Statistics (February 2026); Parliamentary Committee evidence
The distinction between type 1 and type 2 diabetes is clinically and causally fundamental, yet in public discourse the two conditions are often conflated in ways that distort the policy response. Type 1 diabetes — an autoimmune condition in which the body’s immune system destroys the insulin-producing cells of the pancreas — cannot be prevented, has no known cure, and requires lifelong daily insulin management. The UK has the second highest number of children and adolescents with type 1 diabetes in Europe, with over 31,600 cases in 2021, and among those children, there are marked deprivation-related disparities in blood sugar control: average HbA1c levels in the most deprived communities are measurably higher than in the least deprived areas — reflecting the real-world difficulty of managing a complex, technology-dependent condition without adequate support and resources.
Type 2 diabetes is a metabolically different condition: the body becomes progressively resistant to insulin, strongly associated with obesity, physical inactivity, age, ethnicity, and socioeconomic deprivation. What makes the under-40 trend so alarming is that type 2 has historically been considered a disease of middle age and beyond — its rapid penetration into younger age groups suggests that the combination of obesity and sedentary lifestyles is compressing the age of onset by a decade or more. The NHS DiRECT trial’s finding that approximately 50% of participants achieved type 2 remission through a structured very low-calorie diet — reducing their body weight by around 10–15 kg — demonstrates that the condition is not inevitably permanent. But remission requires intensive support, sustained lifestyle change, and structured clinical follow-up that are not yet consistently available at population scale across the NHS.
Diabetes Complications and Weekly NHS Impact in the UK 2026
DIABETES COMPLICATIONS — WEEKLY UK BURDEN (DIABETES UK DATA)
=============================================================
Cases of heart failure per week ████████████████████████████ 2,990
Strokes per week (diabetes-linked) ████████████████████████ 930+
Heart attacks per week ████████████████████ 660
Amputations per week ████████ 184
NHS spend on complications (annual) ████████████████████████████ £6.2 billion
Foot ulcer & amputation cost (E&W) ████████████████████ £837M–£962M/year
Relative CVD risk vs. no diabetes ████████████████████████████ Up to 5× higher
Diabetes-linked premature deaths ████████████████████████████ Significant contributor
► ~80% of NHS diabetes costs relate to managing complications
| Complication / Weekly Burden | Data |
|---|---|
| Heart failure cases per week (diabetes-linked, UK) | 2,990 — Diabetes UK |
| Strokes per week (diabetes-linked) | More than 930 |
| Heart attacks per week (diabetes-linked) | 660 |
| Amputations per week (diabetes-linked) | 184 — Diabetes UK |
| NHS spend annually on diabetes complications (England) | £6.2 billion — approximately 60% of total NHS diabetes spending |
| Annual NHS spend on foot ulcers and amputations alone (England) | £837 million to £962 million per year — DRWF study |
| Potential saving from 33% reduction in foot complications | Over £250 million per year — Diabetes Research & Wellness Foundation |
| Relative cardiovascular disease risk — people with diabetes vs. without | Up to 5 times higher — Diabetes UK |
| Relative stroke risk — people with diabetes vs. without | Up to 5 times higher |
| Blindness and sight loss | Diabetes is the leading cause of preventable sight loss in people of working age in England |
| Kidney failure | Diabetes is a major contributor to kidney failure requiring dialysis or transplant in the UK |
| Share of NHS diabetes spend on complications | Approximately 80% — BritClock 2026 citing NHS/Diabetes UK data |
| Complications share confirmed by York 2024 analysis | ~60% of NHS direct costs relate to complications — just over £6bn of the £10.7bn total |
Source: Diabetes UK — Cost of Complications (June 2024); York Health Economics Consortium / University of York (Diabetic Medicine, June 2024); NHS England — NHS Initiative Helps Thousands More (May 2025); Diabetes Research & Wellness Foundation — Foot Complications Cost Study; BritClock UK Diabetes Statistics 2026
The weekly diabetes complications data published by Diabetes UK conveys the human and financial toll of the disease in terms that no annual figure can fully replicate. 2,990 heart failures, 930 strokes, 660 heart attacks, and 184 amputations every single week in the UK — all attributable to diabetes. That works out to approximately 9,570 cardiovascular events and amputations every seven days, a rate that speaks to how pervasively uncontrolled or under-managed diabetes damages blood vessels, nerves, and organs throughout the body when glucose levels remain elevated over years and decades. The person losing a limb to a diabetic foot complication — and the £837 million to £962 million the NHS spends every year managing such cases — represents the end-state consequence of a care pathway that failed to intervene effectively long before the amputation became necessary.
The comparison of cardiovascular risk is equally stark. People with diabetes are up to five times more likely to develop heart disease or have a stroke compared to those without the condition. For a country already managing a major cardiovascular disease burden, diabetes is a powerful multiplier of that risk — and the two conditions frequently coexist, creating patients with complex multi-system disease who are far more expensive and challenging to manage than either condition in isolation. Diabetes is also the leading cause of preventable sight loss in working-age people in England — a consequence of diabetic retinopathy that the NHS’s annual eye screening programme works to detect early but which still blinds thousands of people every year when screening is missed or treatment is delayed.
Diabetes, Deprivation and Ethnicity in the UK 2026
DIABETES DISPARITIES — DEPRIVATION AND ETHNICITY (UK DATA)
===========================================================
T2D in most deprived quintile (England) ████████████████████████ Highest prevalence
T2D in least deprived quintile ████████████ Lower prevalence
West Midlands — highest T2D prevalence ████████████████████████ 8.6% (regional high)
South East England — lowest prevalence ████████████████ 7.0% (regional low)
T2D and Asian British patients ████████████████████████ Strongly elevated risk
T2D and Black British patients ████████████████████ Elevated risk
T1D and White patients ████████████████████████ Strongest correlation
Under-40s undiagnosed T2D ████████████████████████ More likely undiagnosed
► Type 2 diabetes 2–4× more common in South Asian, Black and other minority communities
| Deprivation / Ethnicity Metric | Data |
|---|---|
| Type 2 diabetes in most deprived quintile vs. least deprived | Strongest positive correlation — T2D registrations strongly associated with most deprived IMD quintile (r≈0.60–0.62) — NDA 2023/24 |
| West Midlands — estimated type 2 diabetes prevalence | 8.6% — highest of any English region (ESMED / OHID data) |
| South East England — estimated type 2 diabetes prevalence | 7.0% — lowest English regional prevalence |
| Type 2 and Asian British patients | Elevated NDA correlation (r≈0.45–0.47) — South Asian communities face 2–4× higher type 2 risk than White European populations at equivalent BMI |
| Type 2 and Black British patients | Elevated NDA correlation (r≈0.40–0.42) — Black communities similarly face elevated type 2 risk |
| Type 1 and White patients | Strongest ethnic correlation for type 1 (r≈0.82–0.85) — autoimmune type 1 has different ethnic distribution to type 2 |
| Undiagnosed type 2 in under-40s | More likely to be living without a diagnosis than older age groups — ONS / Parliamentary evidence |
| Type 2 diabetes doubling rate | Cases among under-40s doubled over past 10 years; under-40 rate now rising faster than over-40 rate — first time this has been observed |
| Gender distribution of UK diabetes (type 1 and type 2 combined) | ~56% male, ~44% female — Statista (2023 National Diabetes Audit data) |
Source: PMC — Comparative Analysis of T1D and T2D Registrations and Risk Factor Correlations (NDA 2022-24, 2025); ESMED / Socio-Economic Deprivation’s Impact on Obesity and Diabetes (September 2025); Statista — Diabetes in England and Wales (December 2024); ONS / Parliamentary Committee written evidence; Chemist-4-U UK Diabetes Statistics (February 2026); BritClock UK Diabetes 2026
The deprivation and ethnicity data on type 2 diabetes in the UK reveals a condition whose distribution is profoundly shaped by the material conditions of people’s lives rather than random biological chance. The strong positive correlation between type 2 diabetes and socioeconomic deprivation — confirmed across the NDA’s 2022-23 and 2023-24 audit periods — reflects the multiple pathways through which poverty increases diabetes risk: cheaper food options being more calorically dense and nutritionally poor, fewer opportunities for physical activity, higher chronic stress levels, and less access to proactive primary care. The West Midlands region, with its concentration of deprived urban communities and significant South Asian and Black British populations, records the highest estimated type 2 prevalence in England at 8.6%, compared to 7.0% in the South East.
For South Asian communities — Bangladeshi, Pakistani, and Indian British populations in particular — the elevated type 2 risk is a well-established clinical reality that operates at a lower BMI threshold than for White European populations. This means that standard BMI-based risk stratification tools underestimate risk in these communities if not adjusted for ethnicity, leading to delayed identification and delayed intervention. The NDA’s finding of r≈0.45–0.47 correlation between type 2 registrations and Asian British patients is consistent with a community that faces disproportionate exposure to the condition’s risk factors and where targeted ethnicity-sensitive screening programmes can deliver significant benefit. The undiagnosed type 2 estimate of 1.3 million people in the UK — particularly those under 40 who are less likely to access regular primary care and may not be offered blood glucose testing — is a clinical and ethical priority in 2026.
NHS Diabetes Prevention and the Healthier You Programme in 2026
NHS HEALTHIER YOU PROGRAMME — KEY DATA (2026)
=============================================
Referrals since launch (2016) ████████████████████████████ 1 million+ (Dec 2025)
Type 2 diabetes risk reduction ████████████████████████ 37% lower risk
Average weight loss (completers) ████████████████████ 3.3 kg
Programme length ████████████████████████████ 9 months
Delivery modes ████████████████████████████ Face-to-face + digital
People referred in E&W (2023) ████████████████████████████ ~650,000 eligible/year
NHS 2022/23 care process failure ████████████████████████████ 1.6M didn't get all 8
Target: 100% coverage of 9 process ████████████ Still not achieved
► Completing the programme reduces risk of developing Type 2 by 37% (Manchester Univ.)
| Prevention / NHS Programme Metric | Data |
|---|---|
| NHS Healthier You Programme — total referrals since 2016 launch | Over 1 million — NHS England announcement, December 2025 |
| Risk reduction for completing the Healthier You Programme | 37% lower chance of developing type 2 diabetes — Manchester University research |
| Average weight loss for programme completers | 3.3 kg — NHS England |
| Programme duration | 9 months — personalised support via face-to-face group or digital pathway |
| People living with diabetes who did not receive all 8 essential care processes (2022/23) | ~1.6 million — Diabetes UK (citing National Diabetes Audit) |
| 9 NHS care processes for people with diabetes | Blood pressure, HbA1c, cholesterol, BMI, creatinine (kidney), urinary albumin, foot examination, eye screening, smoking status |
| People with type 2 receiving all 9 processes (2022/23 NDA) | Approximately 50% — NHS Digital |
| People with type 1 receiving all processes | Lower rate than type 2 — consistent finding across audit periods |
| NHS DiRECT trial — type 2 remission | ~50% achieved remission through structured 800-calorie diet over 12 months |
| Forecast: NHS Healthier You Programme impact | Designed to “reduce the yearly cost of type 2 diabetes on the NHS by £8.8 billion” — original NHS England / Diabetes UK projection |
| Gestational diabetes → structured prevention | Women with GDM advised on post-natal lifestyle support; NHS offering prevention referrals given the 50% five-year type 2 conversion rate |
Source: NHS England — “NHS Diabetes Prevention Scheme Helps One Million People” (December 2025); NHS England — “NHS Initiative Helps Thousands More Tackle Their Diabetes Risk” (May 2025); Diabetes UK — NHS Diabetes Prevention Programme; Diabetes UK — Cost of Complications (June 2024); NHS Digital / National Diabetes Audit 2022/23; NCBI — DIPLOMA long-term assessment of NHS-DPP (NIHR Journals Library, April 2025)
The NHS Healthier You Prevention Programme’s milestone of one million referrals — announced by NHS England in December 2025 — is a genuine achievement in public health at scale, and the evidence behind the programme is robust. Manchester University’s evaluation confirming a 37% reduction in type 2 diabetes risk for those who complete the nine-month programme is one of the stronger prevention effect sizes in UK public health research. The programme’s dual delivery model — face-to-face group sessions and a digital pathway — has proven important for reach, particularly for people in rural areas or with caring responsibilities who cannot attend in person. A NIHR-funded long-term evaluation (DIPLOMA study, April 2025) provides the most comprehensive independent assessment of the programme to date and confirms its clinical and cost-effectiveness at scale.
But the prevention picture is complicated by the persistent failure to deliver the nine annual care processes that every person with diabetes should receive. These processes — HbA1c testing, blood pressure checks, cholesterol measurement, kidney function assessment, eye screening, foot examination, BMI recording, urinary albumin testing, and smoking status review — are the core of ongoing diabetes management and the means by which complications are identified early. Yet in 2022/23, approximately 1.6 million people living with diabetes in England did not receive all eight of their essential care checks. Only around 50% of type 2 diabetes patients completed all nine processes in the same period. The gap between what is recommended and what is consistently delivered in primary care is one of the most significant quality failures in NHS diabetes management — and closing it, according to Diabetes UK, represents one of the highest-value opportunities to reduce complications costs and improve patient outcomes in the system.
Diabetes, Obesity and Lifestyle Risk Factors in the UK 2026
DIABETES RISK FACTORS — UK CONTEXT (2026)
==========================================
Obesity as modifiable risk factor #1 ████████████████████████████ Dominant driver
UK obesity rate (adults) ████████████████████████ ~28%
Overweight + obese combined ████████████████████████████ ~64% of UK adults
T2D in under-40s — doubled (10 yrs) ████████████████████████████ Confirmed
Smoking + diabetes — CVD risk ████████████████████████████ 2× higher
Healthy life expectancy gap (deprived)████████████████████████████ Key driver of T2D risk
South Asian BMI risk threshold ████████████████████████ Lower than White BMI
T2D projected UK total by 2050 ████████████████████████ 4.9 million (T2D only)
► Obesity is the most significant modifiable risk factor for type 2 diabetes
| Risk Factor / Lifestyle Metric | Data |
|---|---|
| Primary modifiable risk factor for type 2 diabetes | Obesity — the most significant single modifiable risk factor; risk is heightened at younger ages |
| UK adult obesity rate (approx.) | ~28% — NHS Digital; combined overweight and obese approximately ~64% of adults |
| Number of people diagnosed with diabetes in England — doubling | From 1.9 million (2000) to 4.4 million+ today — parallels the obesity epidemic trajectory |
| Smoking combined with diabetes — cardiovascular risk | Doubled cardiovascular risk — BritClock (citing NHS data) |
| Type 2 diabetes projection for UK to 2050 | 4.9 million with type 2 alone — European Society of Medicine / OHID analysis |
| Wales projection | Diabetes numbers in Wales could reach ~250,000 by 2029/30 if trends continue — Diabetes UK Cymru |
| South Asian community BMI threshold | Type 2 risk significantly elevated at lower BMI thresholds than White European populations — clinical screening threshold adjusted to BMI 27.5 for South Asian, Chinese, other Asian, Black, or minority ethnic populations in NICE guidance |
| Daily physical inactivity | Key independent risk factor alongside poor diet; sedentary lifestyles driving younger-onset type 2 |
| UK ranking for type 1 diabetes in children (Europe) | 2nd highest in Europe — after Germany (IDF 2021 data) |
| Diabetes mortality costs (indirect) | £3.3 billion annually in productivity losses from premature death and work absence |
Source: NHS Digital / OHID UK Obesity Data; BritClock UK Diabetes Statistics 2026; European Society of Medicine / Socio-Economic Deprivation’s Impact on Obesity and Diabetes (September 2025); Chemist-4-U UK Diabetes Statistics (February 2026); NICE Guidelines for Type 2 Diabetes Risk Assessment; Diabetes UK Cymru projection; University of York / Diabetes UK cost analysis (Diabetic Medicine, 2024)
The relationship between obesity and type 2 diabetes is one of the most tightly documented causal links in modern medicine, and the parallel trajectories of the UK’s obesity epidemic and its type 2 diabetes epidemic are not coincidental — they are the same story told in two different health registers. As UK adult obesity rates have climbed to approximately 28%, and as the combined overweight and obese proportion of the adult population has reached around 64%, type 2 diabetes diagnoses have followed almost exactly the same upward curve, doubling in England over the same period. The alarming development in 2026 is the downward shift in age of onset: for the first time in UK medical history, the rate of new type 2 diagnoses in people under 40 is rising faster than in those over 40. This means that the consequences of two or three decades of uncontrolled type 2 — the cumulative vascular, renal, and neuropathic damage — will increasingly be experienced by people in their 50s and 60s, driving complications costs substantially higher than current projections may capture.
The NICE guideline adjustment of BMI thresholds for South Asian, Chinese, Black and other minority ethnic populations — setting the recommended screening threshold at 27.5 rather than 30 — reflects the clinical reality that insulin resistance and type 2 risk develop at lower body weights in these communities than in White European populations. This is a critical public health consideration for a country as ethnically diverse as the United Kingdom, where communities with elevated baseline diabetes risk are concentrated in urban areas that also face the highest levels of food environment inequality and economic deprivation. Smoking compounds the cardiovascular risk for people already living with diabetes — doubling it relative to non-smoking diabetics — making tobacco cessation one of the highest-priority diabetes management interventions available, even though it is often addressed separately from diabetes care pathways in practice.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.